Johnson & Johnson (JNJ) shares fell sharply on Tuesday, dropping 5.39% to $249.51, a decline of $14.22, even as the healthcare giant posted stronger-than-expected third-quarter results. The company reported higher revenue and lifted its full-year outlook, buoyed by robust pharmaceutical sales. However, a weaker MedTech performance and mounting pressure across international markets weighed heavily on the stock — a reminder that, for a diversified healthcare company, the segment mix behind a headline beat can matter as much as the beat itself.

Strong Q3 Results and Raised Full-Year Guidance

Third-quarter revenue came in at $25.4 billion, topping Wall Street's consensus estimate of $25.28 billion. Adjusted earnings reached $2.59 per share, ahead of the $2.54 analysts had expected. Operational sales climbed 6%, reflecting stronger performance across the company's pharmaceutical portfolio.

Johnson & Johnson also raised its full-year reported revenue forecast to approximately $101.2 billion, up from the $101.1 billion projected previously. The adjusted earnings guidance midpoint moved to $11.10 per share from $11.04. Chief Executive Officer Joaquin Duato attributed the results to product launches and continued innovation.

The company expects operational sales growth of 6.7% to 7.1% for 2026 and anticipates surpassing $100 billion in annual revenue for the first time. Management added that its strategic investments should support double-digit growth by the end of the decade — targets that now serve as reference points for the company's next phase of expansion.

MedTech Weakness Weighs on Shares

Despite the earnings beat, the MedTech division delivered operational sales growth of just 2.5%. Segment revenue of $8.6 billion fell short of Wall Street's $8.71 billion estimate, with cardiovascular and surgical businesses underperforming, particularly outside the United States.

Chief Financial Officer Joe Wolk cited several headwinds affecting the international medical technology business. The Middle East conflict reduced regional healthcare spending, European austerity measures curbed demand, and pricing pressures in China took a toll. Soft sales at the ABIOMED heart pump business — a unit Johnson & Johnson acquired in 2022 — continued to constrain growth. Taken together, the remarks mapped the geopolitical, fiscal, and pricing pressures bearing on the company's device operations outside the United States.

The pharmaceutical segment, by contrast, delivered a strong quarter, with revenue up 7.7% to $16.76 billion. TREMFYA, the company's therapy for autoimmune and inflammatory conditions, saw sales surge 68% to $2.4 billion, well above analysts' estimates of roughly $2.19 billion. DARZALEX, its multiple myeloma treatment, generated $4.24 billion in revenue, up approximately 16%, though it missed market expectations. The gap between the two segments defined the quarter: new drug launches powered overall growth while the medical-device arm ran into a tougher global backdrop.

Orthopedics Spin-Off Targeted for Mid-2027

Johnson & Johnson is continuing preparations to separate its DePuy Synthes orthopedics business, which sells implants and surgical devices, by mid-2027. Management favors a spin-off — a structure that would place shares of the unit directly in the hands of existing shareholders — as the company sharpens its focus on higher-growth pharmaceutical and medical technology operations. The planned separation would mark another major restructuring following the split-off of the Kenvue consumer healthcare unit, completed in 2023.

Reports in September linked Apollo Global Management to potential acquisition talks involving the orthopedics division, with those reports suggesting a transaction could value the business at close to $20 billion. Management, however, is still evaluating its options and has not announced a final transaction structure. Whether the unit ultimately goes to a buyer or to shareholders remains one of the clearest markers of how the company's portfolio transformation will unfold.

Balance Sheet and Outlook

Johnson & Johnson ended the third quarter with approximately $17 billion in cash and marketable securities, alongside $45 billion in debt. The company generated more than $6 billion in free cash flow during the quarter and expects roughly $21 billion for the full year as it advances product launches and restructuring plans.

With 2026 operational sales growth guidance of 6.7% to 7.1%, a mid-2027 separation target, and a $100 billion revenue milestone within reach, the company has set out concrete markers against which its strategy — and its two very different business engines — will be measured in the quarters ahead.

Source: Blockonomi